Tonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million - TNXP News | RalliesTonix Q2 FY26 net loss narrows to $40.55 million; product revenue rises to $13.54 million
T
TNXP• Tonix reports higher product revenue and narrower quarterly loss
- Tonix posted Q2 2026 net sales of $13.54 million, rising from $2 million a year earlier; TONMYA contributed about $11 million.
- Net loss available to common stockholders narrowed to $40.55 million, or $2.44 per share, from $28.27 million, or $3.86 per share.
- R&D expenses climbed to $19.42 million from $10.82 million; SG&A rose to $35.96 million from $16.2 million on launch-related investment.
- Cash and cash equivalents totaled $176.23 million at June 30, 2026; cash runway is expected into early Q2 2027.
- TONMYA prescriptions more than doubled quarter-over-quarter to 12,592; payer coverage expanded to about 136 million covered lives.
•
